Selected Drugs Clear All
MultiCheck Results
- 6
Interactions
Monitor/Modify Tx |
||
|
Cerebyx
(fosphenytoin) + clobazam
(generic) |
||
Monitor/Modify Txfosphenytoin + clobazam monitor respiratory rate: combo may incr. clobazam active metabolite levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism induced, incr. active metabolite formation, additive effects) |
||
|
Cerebyx
(fosphenytoin) + Qudexy XR
(topiramate) |
||
Monitor/Modify Txfosphenytoin + topiramate monitor phenytoin levels: combo may incr. phenytoin levels, risk of toxicity; may decr. topiramate levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism inhibited; hepatic metabolism induced; additive effects) |
||
|
Cerebyx
(fosphenytoin) + rufinamide
(generic) |
||
Monitor/Modify Txfosphenytoin + rufinamide monitor phenytoin levels: combo may incr. phenytoin levels, risk of toxicity; may decr. rufinamide levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (mechanism unknown; hepatic metabolism induced; additive effects) |
||
|
clobazam
(generic) + Qudexy XR
(topiramate) |
||
Monitor/Modify Txclobazam + topiramate monitor respiratory rate: combo may incr. clobazam and active metabolite levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects) |
||
|
clobazam
(generic) + rufinamide
(generic) |
||
Monitor/Modify Txclobazam + rufinamide monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects) |
||
Caution Advised |
||
|
Qudexy XR
(topiramate) + rufinamide
(generic) |
||
Caution Advisedtopiramate + rufinamide caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
Additional Considerations |
||
|
topiramate
in Qudexy XR
|
||
|
beverages or products containing ethanol are contraindicated within 6h of topiramate extended-release (ER) capsules administration; combo may incr. topiramate release rate, levels, risk of adverse effects, decr. duration of efficacy |
||